Health Innovation

We are de-risking biomedical innovations, turning biomedical knowledge into social and economic value.

Health Innovation Assessment

Mercury Pharmaceuticals

Innovators and start-ups in healthcare and biotech are experts in their innovation’s scientific and technical domain but often struggle with navigating the complex world of the healthcare industry.

If you want to objectively show the advantages and competitiveness of your innovation to potential investors, future users, (reimbursement) payers or even the media, you can greatly benefit from Mercury Pharmaceuticals’s Health Innovation Assessment solution.

By making use of robust methods to collect and analyse data, Health Innovation Assessment (HIA) aims to comprehensively assess the added value of (bio-)medical and healthcare innovations. HIA takes into account true multi-stakeholder perspectives on value assessment and the realm of marketplace decision making.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

STAY INFORMED!

Microbiome differences distinguish preterm infants with parenteral nutrition-associated cholestasis

24

Jan 2026

Microbiome differences distinguish preterm infants with parenteral nutrition-associated cholestasis

Microbiome differences distinguish preterm infants with parenteral nutrition-associated cholestasis

Colorblindness linked to delayed bladder cancer detection and higher mortality

24

Jan 2026

Colorblindness linked to delayed bladder cancer detection and higher mortality

Recognizing the sight of blood in urine, the most common first sign of bladder cancer, is often the impetus that leads people to a diagnosis.

Firefighter protective gear restricts movement and may increase injury risk

24

Jan 2026

Firefighter protective gear restricts movement and may increase injury risk

When firefighters respond to an emergency, the gear they wear to protect themselves can also create challenges that could jeopardize their performance and safety.

Selective inhibition of cPLA2 shows promise against Alzheimer's-related brain inflammation

24

Jan 2026

Selective inhibition of cPLA2 shows promise against Alzheimer's-related brain inflammation

A multidisciplinary USC research team has identified new compounds that may target a key driver of brain inflammation linked to Alzheimer's disease. Their research just published in the Nature publication npj Drug Discovery.

Why Us?

KNOWLEDGE OF RESEARCH ENVIRONMENT

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.

UNDERSTANDING INDUSTRIAL NEEDS

Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.

FOCUSED PROJECT MANAGEMENT

Smart approach to project management that helps speed up development stages and decision making.

INVESTMENT CAPABILITY

Availability of own investment up to 2m€ per project allows us to reach the next value milestone.